Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Healios KK Ord Shs HLOSF

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Post by Linda9on Dec 11, 2010 11:26am
375 Views
Post# 17833545

Most Undervalued Juniors Ready to Leap to the Next

Most Undervalued Juniors Ready to Leap to the NextMining companies go through a series of stages from listing on a stock exchange to becoming a producer. A chart of a successful mining stock typically looks as follows:

Figure 1

There are three ways to profit based on the above cycles. First - find a lucky junior exploration company that will make a discovery. Second - buy undervalued shares of stock with established resources for cheap and ride it to production. Third - pinpoint a troubled junior producer at the moment of an operational turnaround.

The second approach is certainly safer than the first and has more upside than the third approach given the project is economically viable and the management has what it takes to capitalize on that.

Sounds easy? Not really, because after months of little news or visible progress by the company, it is difficult to get into a stock that is falling for no comprehensible reason. One can't help but start hesitating. Let's first examine why it is typical to see a stock give up most of its post-discovery gains.

When the speculative new discovery-related hype is over, a waiting period begins. Speculators take profits anticipating that the company will use the high stock price to issue new shares and raise cash.

The stock starts falling and even the loyal shareholders lose patience: why is the stock price falling when the company is making good progress? More and more doubts surface and many shareholders get out. New investors are scared to buy, seeing a falling price.

The main reason stocks often lose most or even all of their discovery gains is their high demand for cash required for preliminary economic programs at the time of zero cash flow and little or no substantive news.

But the company is making progress behind the scenes. They are issuing technical reports, upgrading resources and piecing together various project development studies. The time approaches for a patient and shrewd investor to find exceptional value.


https://www.321gold.com/editorials/sobolev/sobolev102207.html
<< Previous
Bullboard Posts
Next >>